OSTON--(BUSINESS WIRE)--Flex Pharma, Inc. (Nasdaq: FLKS) today announced that on or about June 27, 2019 it will mail a supplement to its proxy materials to provide stockholders with updated information regarding brokers’ discretionary authority to vote stockholders’ shares on Proposal 2 (regarding the reverse stock split) and Proposal 4 (regarding adjournment of the special meeting).

In Flex Pharma’s proxy statement/prospectus/information statement dated April 29, 2019 relating to the special meeting of stockholders (the “Proxy Statement”), Flex Pharma stated that Proposals 1, 2, 3 and 4 in the Proxy Statement are considered non-discretionary matters under the rules of the New York Stock Exchange (“NYSE”) applicable to broker-dealers and, therefore, a stockholder’s broker will not be able to vote the stockholder’s shares of Flex Pharma’s common stock without specific instructions. However, following Flex Pharma’s recent discussion with NYSE, Flex Pharma has determined that Proposals 2 and 4 are considered “routine” matters. Flex Pharma will send the Supplement to advise its stockholders that Proposals 2 and 4 are “routine” matters and that, as such, a broker will have discretion to vote a stockholder’s shares on those proposals even if the broker has received no voting instructions from the stockholder with respect to those proposals.

Flex Pharma previously adjourned the special meeting until July 12, 2019 in order to provide stockholders with more time to complete proxies and vote their shares. Additional shares must be voted for all proposals in order to complete the planned merger with Salarius Pharmaceuticals, LLC, a privately held clinical-stage oncology company targeting the epigenetic causes of cancers.

ADDITIONAL VOTES ARE REQUIRED TO COMPLETE THE MERGER
- URGENT ACTION NEEDED BEFORE July 12, 2019 -

All stockholders are urged to vote as soon as possible “FOR” all proposals in the Proxy Statement by telephone, via the Internet or using the proxy card they received with their proxy materials. For any questions, or assistance in voting shares, or to receive additional copies of the proxy materials, stockholders should call Flex Pharma’s proxy solicitor, Innisfree M&A Incorporated, toll-free at 1 (888) 750-5834.

All stockholders’ votes are important. If Flex Pharma does not complete the merger, it will likely be delisted from Nasdaq and wind-up, which could cause stockholders to lose most of the value of their investment.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, LLC is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. The company’s lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Pediatric Rare Disease Designation by the U.S. Food and Drug Administration. Salarius believes that Seclidemstat is one of only two reversible inhibitors of the epigenetic modulator LSD1 currently in human trials, and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies. Salarius is also developing Seclidemstat for a number of cancers with high unmet need and expects to commence additional clinical studies in 2019 targeting advanced solid tumors, including prostate, breast and ovarian cancers. For more information, please visit salariuspharma.com.

About Flex Pharma

Flex Pharma, Inc. is a biotechnology company that was founded in 2014 by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate) and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology.